Avadel Pharmaceuticals PLC
Company Profile
Business description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Contact
10 Earlsfort Terrace
Dublin 2
DublinD02 T380
IRLT: +353 19015201
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
188
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,518.30 | 51.30 | 0.61% |
| CAC 40 | 7,850.10 | 106.35 | 1.37% |
| DAX 40 | 23,566.54 | 67.22 | 0.29% |
| Dow JONES (US) | 42,410.10 | 1,160.72 | 2.81% |
| FTSE 100 | 8,604.98 | 50.18 | 0.59% |
| HKSE | 23,181.14 | 368.32 | -1.56% |
| NASDAQ | 18,708.34 | 779.43 | 4.35% |
| Nikkei 225 | 38,296.86 | 652.60 | 1.73% |
| NZX 50 Index | 12,748.29 | 71.54 | 0.56% |
| S&P 500 | 5,844.19 | 184.28 | 3.26% |
| S&P/ASX 200 | 8,274.70 | 41.20 | 0.50% |
| SSE Composite Index | 3,375.48 | 6.24 | 0.19% |